Research - Infectious Diseases Fellowship Program

Areas of active basic science, translational, and clinical Infectious Diseases research include:

  • Antimicrobial Stewardship: Provider Reports, Best Practice Alerts
  • HIV: PreP among Racially Diverse Trans-Women in the Deep South
  • Transplantation: HOPE in Action, Fungal Infections, Antibiotic Stewardship, Diagnostic Stewardship

View Research Opportunities at Ochsner

Active Clinical Trials

T’Cher, Take Charge: Increasing PrEP awareness, uptake and adherence through health care empowerment and addressing social determinants of health among racially diverse trans women in the Deep South
Site PI: Narquis Barak

T’Cher NOLA is devoted to the health and wellness of women of transgender experience in the New Orleans area through education, research, and engagement.

YouTube Logo

Watch Take Charge Ochsner

Ochsner's Low Barrier Infection Prevention Study aka SPARK, Sexual Health, Prevention, Access, Research, and Knowledge
Site PI: Narquis Barak

Multiple Patient Program for Lamprene® (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections
Site PI: Poppy Markwell, MD

Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections
Site PI: Poppy Markwell, MD

Kidney Transplantation in Recipients and Donors with HIV: Long Term Follow Up Study
Site PI: Jonathan Hand, MD

A Study of Vaccination with 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60-Years and Older with a History of Urinary Tract Infection in the Past 2 Years
Site PI: Jonathan Hand, MD

A Phase 4 Study Using a Test-Negative Design to Evaluate the Effectiveness of a 20-valent Pneumococcal Conjugate Vaccine against Vaccine-Type Radiologically-Confirmed Community-Acquired Pneumonia in Adults ≥65 Years of Age
Site PI: Jonathan Hand, MD

Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)
Site PI: Jonathan Hand, MD

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides difficile infection
Site PI: Jonathan Hand, MD

A Phase 3, placebo-controlled, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of a Clostridioides difficile vaccine in adults 65 years of age and older
Site PI: Jonathan Hand, MD

A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides difficile Infection in Individuals 18 Years of Age and Above
Site PI: Jonathan Hand, MD

A single-arm, open-label, prospective, observational study to assess the safety of sulbactam-durlobactam, including the risk of hypersensitivity reactions including anaphylaxis in participants with Acinetobacter baumannii-calcoaceticus complex infection
Site PI: Jonathan Hand, MD

A prospective randomized basket trial evaluating the clinical utility of plasma-based microbial cell-free metagenomic sequencing for diagnosis and management of suspected infections in adult immunocompromised outpatients
Site PI: Jonathan Hand, MD

Why Choose Ochsner?

Why Choose Ochsner Video

Ochsner Health is the leading nonprofit healthcare system in the Gulf South, serving patients across Louisiana, Mississippi, and surrounding regions.

  • 47 hospitals and more than 370 health and urgent care centers
  • Over 40,000 team members
  • Approximately 4,900 employed and affiliated physicians
  • Care for 1.6 million patients annually from all 50 states and dozens of countries